Journal Information
Vol. 43. Issue S3.
Pages S47-S48 (November 2021)
Share
Share
Download PDF
More article options
Vol. 43. Issue S3.
Pages S47-S48 (November 2021)
STEM CELL TRANSPLANTPP 39
Open Access
THE ROLE OF SUBPOPULATIONS OF MOBILIZED PERIPHERAL HEMATOPOIETIC STEM CELLS IN THE RESTORATION OF HEMATOPOIESIS DURING HIGH-DOSE CHEMOTHERAPY IN CANCER PATIENTS
Visits
926
Liudmila GRIVTSOVA1, Nikolai TUPITSYN2
1 A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
2 FSBI NMITs oncology named after N.N. Blokhin "of the Ministry of Health of Russia
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 43. Issue S3
More info
Objective

Mobilized peripheral hematopoietic stem cells are transplanted to cancer patients as support for high-dose chemotherapy. It is believed that the effectiveness of restoring all hematopoietic sprouts during HSC transplantation depends on the total dose of CD34+ cells. At the same time, CD34+ stem cells are a heterogeneous cell pool, including progenitor cells of different levels of differentiation and different ability to proliferate. Accordingly, it can be expected that the subpopulation composit.

Methodology

We have studied of HSC subsets in 569 specimens of hemopoietic tissue (blood cells and LP cells) from 167 adult cancer patients and on 557 specimens of hemopoietic tissue from 263 pediatric cancer patients. Also, 61 samples of LP from 50 healthy HSC donors were studied. All patients were managed at bone marrow transplantation units of hematology malignancy and oncology department of N.N. Blokhin Cancer Research Center from 1996 to 2014.

Results

Peripheral hemopoietic stem cells (HSC) that are transplanted to cancer patients to reduce critical pancytopenia vary in subset composition and include early polypotent precursors (CD38- and/or HLA-DR-, CD90+, CD45-negative), lymphoid precursors (CD10+, CD7+, CD2+, CD19+, CD56+), megakaryocyte- (CD61+) and myeloid-committed precursors (CD117+, CD13+, CD33+). These subsets of early and committed HSC are found in different proportions in cancer patients and normal donors.

Conclusion

So, the pool of mobilized HSC is heterogeneous and represented by pluripotent precursors and committed HSC in different proportions that are in variable, rather sophisticated interrelations. Mobilization effect of SC individual subsets is related with disease type. To achieve fast recovery of granulocyte lineages after HSC autologous or allogeneic transplantation one should not focus only on proportion of committed myeloid HSC: optimal HSC content to be transplanted should be in a certain balance.

Full text is only aviable in PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools